


PHARMACEUTICAL 2023

Ensysce Biosciences Inc. Rank 428 of 446











Ensysce Biosciences Inc. Rank 428 of 446

The relative strengths and weaknesses of Ensysce Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ensysce Biosciences Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Ensysce Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 280% points.

The company's Economic Capital Ratio, given in the ranking table, is -394%, being 437% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	5,299
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,464
Liabilities, Non-Current	450
Other Assets	586
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	14
Other Revenues	2,523
Property and Equipment	0
Research and Development	19,836
Selling, General and Administrative Expense	6,910

Output Variable	Value in 1000 USD
Assets	5,885
Liabilities	9,915
Expenses	26,745
Revenues	2,523
Stockholders Equity	-4,030
Net Income	-24,208
Comprehensive Net Income	-24,208
Economic Capital Ratio	-394%

